Texas
LATEST FROM BIOSPACE
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
A new study was published this week and proposed a potential new biomarker for predetermining patient responsiveness to immune checkpoint blockade therapy.
Yet another busy week for clinical trial news. Here’s a look.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.
Here’s a look at a few of the industry expansions that have been announced so far this month.
PRESS RELEASES